---
layout: default
title: Dupilumab
description: "Dupilumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 64
evidence_level: L3
indication_count: 10
---

# Dupilumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Dupilumabï¼šå¾ç•°ä½æ€§çš®è†šç‚åˆ°æ”¯æ°£ç®¡ç‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Dupilumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Dupilumab åŸæœ¬ç”¨æ–¼æ²»ç™‚ä¸­è‡³é‡åº¦ç•°ä½æ€§çš®è†šç‚ã€æ°£å–˜åŠæ…¢æ€§é¼»ç«‡ç‚åˆä½µé¼»æ¯è‚‰ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ”¯æ°£ç®¡ç‚ (bronchitis)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **1 å€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç•°ä½æ€§çš®è†šç‚ã€æ°£å–˜ã€æ…¢æ€§é¼»ç«‡ç‚åˆä½µé¼»æ¯è‚‰ã€å—œä¼Šç´…æ€§é£Ÿé“ç‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | bronchitisã€çš®è†šç‚ã€acne keloidã€exanthem (disease)ã€neonatal dermatomyositisã€acrodermatitis chronica atrophicansã€amyopathic dermatomyositisã€secondary interstitial lung disease specific to childhood associated with a connective tissue diseaseã€hydroa vacciniforme, familialã€atopic eczema |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.92% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. bronchitis</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.92%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Dupilumab æ˜¯ä¸€ç¨®äººæºåŒ–å–®æ ªæŠ—é«”ï¼Œå¯é˜»æ–· IL-4 å’Œ IL-13 çš„è¨Šè™Ÿå‚³éï¼Œ
é€™å…©ç¨®ç´°èƒå› å­æ˜¯ç¬¬äºŒå‹ç™¼ç‚åæ‡‰çš„é—œéµä»‹è³ªã€‚æ”¯æ°£ç®¡ç‚ï¼Œç‰¹åˆ¥æ˜¯å—œé…¸æ€§æ”¯æ°£ç®¡ç‚ï¼Œ
æ¶‰åŠé¡ä¼¼çš„ç™¼ç‚æ©Ÿè½‰ã€‚Dupilumab å·²æ ¸å‡†ç”¨æ–¼å—œé…¸æ€§ç™½è¡€çƒè¡¨ç¾å‹çš„æ°£å–˜ï¼Œ
å…¶å°ä¸‹å‘¼å¸é“ç™¼ç‚çš„æŠ‘åˆ¶ä½œç”¨å¯èƒ½å»¶ä¼¸è‡³æ”¯æ°£ç®¡ç‚çš„æ²»ç™‚ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT04362501](https://clinicaltrials.gov/study/NCT04362501) | Phase 2 | COMPLETED | 33 | è©•ä¼° dupilumab åœ¨ç„¡é¼»æ¯è‚‰çš„æ…¢æ€§é¼»ç«‡ç‚æ‚£è€…çš„ç™‚æ•ˆ |
| [NCT03346434](https://clinicaltrials.gov/study/NCT03346434) | Phase 2/3 | COMPLETED | 202 | è©•ä¼° dupilumab åœ¨ 6 å€‹æœˆè‡³ 6 æ­²ç•°ä½æ€§çš®è†šç‚å…’ç«¥çš„è—¥å‹•å­¸å’Œç™‚æ•ˆ |
| [NCT01949311](https://clinicaltrials.gov/study/NCT01949311) | Phase 3 | COMPLETED | 2733 | Dupilumab åœ¨ç•°ä½æ€§çš®è†šç‚æˆäººæ‚£è€…çš„é•·æœŸå®‰å…¨æ€§ç ”ç©¶ |
| [NCT04287621](https://clinicaltrials.gov/study/NCT04287621) | N/A | ACTIVE_NOT_RECRUITING | 718 | RAPID ç™»è¨˜ç ”ç©¶ï¼šæ°£å–˜æ‚£è€…ä½¿ç”¨ dupilumab çš„çœŸå¯¦ä¸–ç•Œæ•¸æ“š |
| [NCT02277769](https://clinicaltrials.gov/study/NCT02277769) | Phase 3 | COMPLETED | 708 | ç¢ºèª dupilumab å–®è—¥æ²»ç™‚ä¸­è‡³é‡åº¦ç•°ä½æ€§çš®è†šç‚çš„ç™‚æ•ˆ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [34597534](https://pubmed.ncbi.nlm.nih.gov/34597534/) | 2022 | RCT extension | Lancet Respir Med | TRAVERSE ç ”ç©¶ï¼šdupilumab åœ¨ä¸­è‡³é‡åº¦æ°£å–˜çš„é•·æœŸå®‰å…¨æ€§å’Œç™‚æ•ˆ |
| [30273510](https://pubmed.ncbi.nlm.nih.gov/30273510/) | 2019 | Meta-analysis | J Asthma | Dupilumab åœ¨æ§åˆ¶ä¸ä½³æ°£å–˜çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ç³»çµ±æ€§å›é¡§ |
| [38488768](https://pubmed.ncbi.nlm.nih.gov/38488768/) | 2024 | Case report | Pediatr Pulmonol | Dupilumab ç”¨æ–¼å…’ç«¥å—œé…¸æ€§å¡‘å‹æ€§æ”¯æ°£ç®¡ç‚çš„æ–°ç™‚æ³• |
| [30196731](https://pubmed.ncbi.nlm.nih.gov/30196731/) | 2018 | Review | Expert Opin Pharmacother | å¸è¸ç›¸é—œæ°£é“ç–¾ç—…åˆä½µæ°£å–˜çš„æ²»ç™‚æŒ‘æˆ° |
| [32428511](https://pubmed.ncbi.nlm.nih.gov/32428511/) | 2020 | Clinical study | Chest | æŠ— T2 ç”Ÿç‰©è£½åŠ‘æ²»ç™‚å°é¡å›ºé†‡ä¾è³´å‹æ°£å–˜è‚ºé€šæ°£çš„å½±éŸ¿ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. dermatitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.71%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. acne keloid</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.61%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.61%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. exanthem (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.57%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. neonatal dermatomyositis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.56%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.56%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. acrodermatitis chronica atrophicans</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.54%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.54%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. amyopathic dermatomyositis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.53%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.53%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. secondary interstitial lung disease specific to childhood associated with a connective tissue disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.52%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.52%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. hydroa vacciniforme, familial</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.50%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.50%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. severe nonproliferative diabetic retinopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.10%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.10%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| 2 å¼µè¨±å¯è­‰ | æœé¿ç‚æ³¨å°„åŠ‘300æ¯«å…‹ | æ³¨å°„åŠ‘ | ç•°ä½æ€§çš®è†šç‚ã€æ°£å–˜ã€æ…¢æ€§é¼»ç«‡ç‚åˆä½µé¼»æ¯è‚‰ã€å—œä¼Šç´…æ€§é£Ÿé“ç‚ã€COPDã€æ…¢æ€§è‡ªç™¼æ€§è•éº»ç–¹ |

## å®‰å…¨æ€§è€ƒé‡

- **å¸¸è¦‹ä¸è‰¯åæ‡‰**ï¼šæ³¨å°„éƒ¨ä½åæ‡‰ã€çµè†œç‚ã€å£å”‡çš°ç–¹
- **é‡è¦æ³¨æ„äº‹é …**ï¼šé–‹å§‹æ²»ç™‚å‰æ‡‰è©•ä¼°å¯„ç”ŸèŸ²æ„ŸæŸ“ï¼Œä¸å»ºè­°èˆ‡æ´»ç—…æ¯’ç–«è‹—åŒæ™‚ä½¿ç”¨
- **ç‰¹æ®Šæ—ç¾¤**ï¼šå…’ç«¥ä½¿ç”¨éœ€æŒ‰é«”é‡èª¿æ•´åŠ‘é‡


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Helminthiasis** ğŸŸ¡ Moderate
- Patients with preexisting-existing helminth infections should be treated prior to therapy with dupilumab.  It is recommended to discontinue treatment with dupilumab if patients become infected while on treatment and if they are not responding to trea...

**Vision Disorders** ğŸŸ¡ Moderate
- Conjunctivitis and keratitis may occur while on treatment with dupilumab.  Care should be exercised when using this agent in patients with visual defects.  Patients should be closely monitored for new onset or worsening eye symptoms.

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Dupilumab æŠ‘åˆ¶ IL-4/IL-13 çš„æ©Ÿè½‰é©ç”¨æ–¼å—œé…¸æ€§ç™¼ç‚ç›¸é—œçš„æ”¯æ°£ç®¡ç‚ï¼Œ
å·²æœ‰ç—…ä¾‹å ±å‘Šæ”¯æŒå…¶åœ¨å—œé…¸æ€§å¡‘å‹æ€§æ”¯æ°£ç®¡ç‚çš„ç™‚æ•ˆã€‚éœ€å€åˆ†æ”¯æ°£ç®¡ç‚çš„äºå‹ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å€åˆ†å—œé…¸æ€§èˆ‡éå—œé…¸æ€§æ”¯æ°£ç®¡ç‚çš„ç”Ÿç‰©æ¨™è¨˜
- é‡å°æ…¢æ€§æ”¯æ°£ç®¡ç‚æ‚£è€…çš„å‰ç»æ€§è‡¨åºŠè©¦é©—
- èˆ‡ COPD åˆä½µå—œé…¸æ€§ç™½è¡€çƒå¢é«˜æ‚£è€…çš„æ²»ç™‚æ•ˆç›Šè©•ä¼°


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Propantheline]({{ "/drugs/propantheline/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Alfacalcidol]({{ "/drugs/alfacalcidol/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dorzolamide]({{ "/drugs/dorzolamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Dupilumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/dupilumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_dupilumab,
  title = {Dupilumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/dupilumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
